Lyvispah: A Guide to Reducing Drooling in Children
Lyvispah (glycopyrronium bromide) is a prescription oral solution used to reduce pathological drooling in children 3 to 5 years old with a neurologically impaired condition, such as cerebral palsy. It works by reducing saliva production. Use only as directed by the child's prescribing clinician.
Lyvispah is a weight-based liquid medicine usually given three times daily to reduce excessive drooling in certain children. It can cause important side effects, including dry mouth, constipation, and difficulty urinating, so dosing should be managed by a clinician.
Key facts at a glance
- RxNorm
- 2586590
- Generic
- Lyvispah
- Class
- brand-name
- Brands
- —
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy